ATC Group: L01ED02 Ceritinib

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of L01ED02 in the ATC hierarchy

Level Code Title
1 L Antineoplastic and immunomodulating agents
2 L01 Antineoplastic agents
3 L01E Protein kinase inhibitors
4 L01ED Anaplastic lymphoma kinase (ALK) inhibitors
5 L01ED02

Active ingredients in L01ED02

Active Ingredient Description
Ceritinib

Ceritinib is an orally highly selective and potent ALK inhibitor. Ceritinib inhibits autophosphorylation of ALK, ALK-mediated phosphorylation of downstream signalling proteins and proliferation of ALK-dependent cancer cells both in vitro and in vivo.

Related product monographs

Title Information Source Document Type  
ZYKADIA Hard capsule European Medicines Agency (EU) MPI, EU: SmPC

Medicines in this ATC group

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Estonia (EE)

France (FR)

Hong Kong (HK)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

Romania (RO)

Singapore (SG)

Spain (ES)

Turkey (TR)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.